title: [Therapeutic results with apl 93 protocol in acute promyelocytic leukemia (34 cases)].
abstract: BACKGROUND
  Acute promyelocytic leukaemia (APL) account for approximately 10% to 15% of all AML in most reports. Clinical features includes the presence in 80% to 90% of patients of a severe hemorrhagic syndrome, a specific balanced translocation between chromosomes 15 and 17 with a fusion of a large pert of the retinoic acid receptor a gene (RARa) on chromosome 17 to a part of the promyelocytic leukaemia (PML) gene on chromosome 15. More than 75% of patients (under 65 years of age) can be cured, with the application of a combination of anthracyclines and all-trans retinoic acid (ATRA), followed by maintenance therapy.
  
  
  OBJECTIVE
  of the study was to assess of the therapeutic management of APL 93 protocol in acute promyelocytic leukemia.
  
  
  METHODS
  We present here the results of a retrospective study concerning 34 patients with APL included between 1998 and 2004 in the APL 93 protocol : 20 in group B and 14 in group C. CR was 82 %.
  
  
  RESULTS
  Failure is only due to toxic death (18%) Event free survival at 4 years is 63,47% with relapse rate at 14.25%. Overall survival at 4 years is 69,72%. Our results are acceptable and can be improved with reduction of failure due to toxic death, probably with omission of cytarabine from induction and consolidation adapted by the Spanish PETHEMA Group.
authors.affiliation: Service d'hématologie de I'hôpital Aziza Othmunana Tunis.
authors.forename: Ramzi
authors.initials: R
authors.lastname: Jeddi
authors.forename: Sondes
authors.initials: S
authors.lastname: Hdiji
authors.forename: Karima
authors.initials: K
authors.lastname: Kacem
authors.forename: Raihane
authors.initials: R
authors.lastname: Ben Lakhal
authors.forename: Lamia
authors.initials: L
authors.lastname: Aissaoui
authors.forename: Hela
authors.initials: H
authors.lastname: Ben Abid
authors.forename: Zaher
authors.initials: Z
authors.lastname: Belhadj Ali
authors.forename: Balkis
authors.initials: B
authors.lastname: Meddeb
mesh_terms: D000293:Adolescent; D000328:Adult; D018943:Anthracyclines / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002884:Chromosomes, Human, Pair 15 / Q000235:genetics; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D018168:Receptors, Retinoic Acid; D012074:Remission Induction; D000072482:Retinoic Acid Receptor alpha; D012189:Retrospective Studies; D016019:Survival Analysis; D014178:Translocation, Genetic; D014212:Tretinoin / Q000008:administration & dosage; D014416:Tunisia
chemical_list: D018943:Anthracyclines; C000607071:RARA protein, human; D018168:Receptors, Retinoic Acid; D000072482:Retinoic Acid Receptor alpha; D014212:Tretinoin